Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine [BRE15]
For treating adult patients with previously untreated stage III or IV Hodgkin lymphoma where the following criteria have been met:
- This application is being made by and the first cycle of brentuximab in combination with doxorubicin, vinblastine and dacarbazine will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
- The patient is an adult.
- The patient has previously untreated CD30 positive Hodgkin lymphoma.
- The patient has stage III or IV Hodgkin lymphoma. Please mark below which stage applies to this patient:
- stage III disease or
- stage IV disease Note: the use of brentuximab plus chemotherapy is not commissioned in stage I or II Hodgkin lymphoma.
- Brentuximab will be given in combination with doxorubicin, vinblastine and dacarbazine (AVD).
- A maximum of 6 x 28 day cycles of brentuximab plus AVD will be administered to this patient. Note: there is no PET-adapted approach to treatment escalation or de-escalation with this brentuximab-AVD combination.
- The prescribing clinician is aware that the scheduled brentuximab dose per day 1 and day 15 administrations is 1.2mg/Kg (ie not the dose used when brentuximab is given as monotherapy).
- The prescribing clinician is aware that the brentuximab SPC recommends that primary prophylaxis with GCSF should begin with the first dose of brentuximab-AVD.
- The patient has an ECOG performance status of 0 or 1 or 2.
- The prescribing clinician is aware that when a treatment break of more than 6 weeks beyond the expected 4-weekly cycle length is needed, I will complete a treatment break approval form.
- Brentuximab will otherwise be used as set out in its Summary of Product Characteristics (SPC).
CDF funded From: 02 April 2025
Additional information
Current Form Version
Important
This is an older version of the form. To view the most up to date form follow this link